Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
This study is testing a treatment called viral specific cytotoxic t-lymphocytes (CMV specific CTLs) for people with cytomegalovirus (CMV) infections that haven't responded to other treatments. These special immune cells are collected from a donor and then given to patients. The study aims to see how safe this treatment is and if it helps reduce the CMV infection. It includes children, adolescents, and young adults (ages 1 month to 79 years) who have CMV after a stem cell transplant, with certain immune problems, or after an organ transplant. The study is currently recruiting up to 20 participants.
- Study design
- This is an interventional study planning to enroll 20 participants. The phase of the study is not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 12 weeks after each infusion to check for side effects and treatment response.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
At a glance
Conditions
Where it's being run
9 sites across 8 statesStudy leadership
- Mitchell S Cairo, MD · PRINCIPAL_INVESTIGATOR · New York Medical College
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Patients will be followed for 12 weeks after each infusion
Patients will be monitored for adverse events following the administration of CMV CTLs
- Incidence of Response to TreatmentPatients will be followed 12 weeks after each infusion
Patients will be followed for improvement in viral infection by monitoring CMV PCR weekly for response to treatment with CTLs